NLNK News and Press, NewLink Genetics From 11/01/18

AMES, Iowa, Nov. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that an abstract with data pertaining to the use of the Company's investigational immuno-oncology molecule, indoximod, in combination therapy for patients with newly diagnosed acute ...

AMES, Iowa, Oct. 30, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK), a clinical stage biopharmaceutical company focused on developing novel immuno-oncology therapeutic candidates, announced today it will present at the Stifel 2018 Healthcare Conference. The conferen...

AMES, Iowa, Oct. 18, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its third quarter 2018 financial results on Thursday, November 1, 2018. The company has scheduled a conference call for 4:30 PM ET the same day to d...

NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of ChemoCentryx, Inc. (NASDAQ:CCXI), Armstrong Flooring, Inc. (NYSE:AFI),...

Please note that I am affiliated with Avisol Capital Partners and their Total Pharma Tracker service. They have also covered the companies in this article in their writings, and I wanted to make readers aware of the potential for overlapping coverage. NewLink Genetics ( NLNK ) ha...

AMES, Iowa, Oct. 01, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) announced today that two abstracts were accepted for presentation at the Society for Immunotherapy of Cancer (SITC) 33 rd Annual Meeting being held November 7-11, 2018 in Washington, D.C.  Th...